New Technology– category –
-
FDA Grants Accelerated Approval to Nuvalent’s Zidesamtinib (Jideytro) for ROS1-Positive NSCLC, Two Months Ahead of PDUFA Date
FDA USA Overview On July 22, 2026, the FDA approved Nuvalent, Inc.'s zidesamtinib (Jideytro) for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) previously treated with at least one ROS... -
Generative AI Forges Unprecedented Flavor Molecules, Reshaping the Food Industry
Industry Today USA Overview Generative AI has achieved a significant breakthrough in molecular biology, enabling the de novo design of entirely new flavor molecules that do not exist in nature. This sophisticated system analyzes vast che... -
Agentic and Generative AI to Revolutionize Cardiovascular Drug Discovery
American Heart Association Journals USA Overview Large Language Models (LLMs) and agentic AI are poised to fundamentally transform cardiovascular disease (CVD) drug development by enhancing target understanding, accelerating novel compou... -
FDA Grants Accelerated Approval to Regeneron’s Bispecific Antibody Linvoseltamab (LYNOZYFIC) for Multiple Myeloma
International Myeloma Foundation USA Overview The International Myeloma Foundation reported that LYNOZYFIC (linvoseltamab-gcpt), a BCMA-CD3 bispecific antibody immunotherapy, received accelerated FDA approval in July 2025. This drug targ... -
First-in-Class EGFR-HER3 Bispecific ADC Iza-Bren Achieves 48.1% ORR in Phase Ib for Extensive-Stage Small Cell Lung Cancer
ASCO Publications USA Overview Results from a Phase Ib study of Izalontamab Brengitecan (Iza-Bren), the first-in-class EGFR-HER3 bispecific antibody-drug conjugate (ADC) for extensive-stage small cell lung cancer (SCLC), have been announ... -
ARNT Molecular Glue Degrader NEO-811 Initiates Phase 1/2 First-in-Human Study for Unresectable Clear Cell Renal Cell Carcinoma
Medical Oncology and Hematology Global Overview The NEO-811-101 study has commenced as an open-label, first-in-human, Phase 1/2 dose-escalation and expansion study of the ARNT molecular glue degrader, NEO-811. Targeting patients with loc... -
bioRxiv Preprint: Novel ‘Post-Loading’ Strategy for RNA into Empty Lipid Nanoparticles Solves Cold Chain Challenges
bioRxiv USA Overview A bioRxiv preprint introduces a novel 'post-loading' strategy for RNA into lipid nanoparticle (LNP) carriers. This method allows empty LNPs to be manufactured and stored separately, with RNA loaded just prior to admi... -
Sanofi Unveils ‘Dual-Targeting Library 2.0’ to Accelerate Novel Bispecific Therapeutic Design
Sanofi France Overview Sanofi has announced its innovative 'Dual-Targeting Library (DTL) 2.0' approach for designing novel bispecific therapeutics. This strategy combines monospecific antibodies and nanobodies to build extensive bispecif... -
Mapping AI Drug Discovery: Key Players Lead Across Target Identification, Generative Design, and Clinical Optimization
Unknown Global Overview A new article maps the AI drug discovery landscape into four key layers: biological target identification, generative molecule design, automated experimentation, and clinical trial optimization. Recursion Pharmace... -
World Economic Forum Names Exosome DDS and Personalized mRNA Cancer Vaccines as Top Emerging Technologies for 2026
World Economic Forum Global Overview The World Economic Forum's 'Top 10 Emerging Technologies of 2026' report details exosome drug delivery systems (DDS) and personalized mRNA cancer vaccines as key innovations. Exosome DDS leverages the...
